Correvio nets $12.8mm via FOPO
Correvio Pharma Corp. netted $12.8mm through the follow on sale of 9.2mm common shares (including full exercise of the overallotment) at $1.50 each. The company will use the funds to file the NDA for IV Brinavess (vernakalant) for atrial fibrillation, for business development activties, and to meet the minimum liquidity requirements under its loan agreement with CRG.
- Specialty Pharmaceuticals
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com